Full Press Release Details
XBRL data with the SEC
Melbourne, Australia, October 29, 2019:
Immuron Limited (ASX: IMC; NASDAQ: IMRN) ("Immuron" or the "Company"), an Australian biopharmaceutical
company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut-mediated pathogens,
advises that, the Company is required by the Securities and Exchange Commission (SEC) to provide the Company's financial
statements in an interactive data format using eXtensible Business Reporting Language (XBRL).
purpose of this release is to advise that further to the Form 20-F filing as announced on 28 October 2019, the Company has also
filed the XBRL interactive data with the SEC, which is available via the company website at https://www.immuron.com.au/corporate-directory-and-governance/.